http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2633055-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7993f3941238bbeb7b25ce1964fd0eed |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-22 |
| filingDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_934c8fda1f488a370918048aa30c6f7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29218c9fe84ac408e12b5e62ea7a834a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa17f2287fe5a4925d2c58dec08921ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca7ba8efad5dbd1c959e70a3e1874274 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_900faa33b72545e683a8328f6cd659a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86dce30b0e7a3105b40ae89bbe145682 |
| publicationDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2633055-C1 |
| titleOfInvention | Ophthalmic composition for treatment of conjunctivites, bleparitis and marginal corneal ulcers in topical application |
| abstract | FIELD: pharmacology. n SUBSTANCE: invention is an ophthalmic composition containing an active substance, excipients and a consistent-forming base, characterised by containing (11beta,16alpha)-16,17-(butylidenbis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione(budesonide) and hyaluronic acid or sodium hyaluronate as an active substance, and boric acid as an auxiliary substance, the components in the composition being in a certain ratio %. n EFFECT: increased therapeutic effectiveness of the claimed composition due to the combined action of budesonide and a hyaluronic acid source with prolonged drugs action and increased contact time of the composition with the eye cornea, reduced therapy course, excluded relapses of diseases and complications, and also a low degree of absorption with more pronounced action, simplicity in performance and good tolerability of patients suffering from eye inflammatory diseases of non-infectious etiology and allergic lesions of the ocular surface. n 2 cl, 4 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2679319-C1 |
| priorityDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.